Fujirebio Diagnostics Announces FDA Clearance of Lumipulse G B•R•A•H•M•S PCT Assay

Fujirebio Diagnostics Announces FDA Clearance of Lumipulse G B•R•A•H•M•S PCT Assay

MALVERN, PA — Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings Inc., has received U.S. Food and Drug Administration (FDA) clearance of the company’s Lumipulse® G B•R•A•H•M•S PCT Assay for testing on its LUMIPULSE® G1200 immunoassay platform.

Procalcitonin (PCT) is a biomarker specific to bacterial infections. PCT offers advantages as an aid to guide antibiotic treatment decisions or to assess the risk of critically ill patients for progression to sepsis or septic shock.

The Lumipulse® G B•R•A•H•M•S PCT Assay, when run on the LUMIPULSE®G1200 immunoassay platform, and used in conjunction with other laboratory findings and clinical assessments, can aide in:

  • Decision-making for patients with suspected or confirmed lower respiratory tract infection
  • Risk assessment of critically ill patients on their first day of intensive care unit (ICU) admission for progression to severe sepsis or septic shock
  • The cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock in the ICU, or obtained in the emergency department or other hospital setting prior to ICU admission, by measuring a change in PCT level over time
  • Decision-making for patients with suspected or confirmed sepsis
READ:  Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder

The Lumipulse® G B•R•A•H•M•S PCT Assay offers excellent precision with a CV of ≤4.7%. With a precise assay, clinicians can more accurately determine the change in PCT levels and, therefore, the effectiveness of antibiotics, as well as make more informed antibiotic initiation and discontinuation decisions. By removing analytical variability of test results when monitoring antibiotic therapy, the Lumipulse® G B•R•A•H•M•S PCT Assay helps conform to new guidelines for antibiotic stewardship as released by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.

“Serial measurement of procalcitonin levels is a significant innovation for antibiotic stewardship, which can lead to reduced hospitalization stays without adversely affecting patient outcomes,” says Matthew Bell, Vice President Sales and Marketing at Fujirebio, US. “The Lumipulse® G B•R•A•H•M•S PCT Assay is a significant new tool in the fight against sepsis, lowering hospital re-admission rates, and improving the use of antibiotic treatment.”

READ:  PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients

Source: Fujirebio Diagnostics, 205 Great Valley Pkwy, Malvern PA 19355

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee